Resources

Following our webinar, The Greatest Hits: A Beginner's Guide to High-Quality Starting Points for Drug Discovery, Symeres experts answer audience questions on hit discovery, screening strategy and lead optimisation. Explore insights on carbohydrate scaffolds, natural products, library design and how the SymeGold collection supports successful drug discovery programmes.

Explore the challenges of predicting drug-induced liver injury (DILI) during preclinical development and discover how emerging in vitro approaches can support earlier, more informed safety assessment. This on-demand webinar examines key biological mechanisms behind DILI, current limitations in detection strategies, and evolving scientific perspectives shaping the future of hepatotoxicity evaluation.

Watch this on-demand webinar to learn how to identify high-quality starting points in drug discovery and set your program up for success. Discover how early decisions around screening, chemistry, and strategy can reduce risk and accelerate progression.

Most drug candidates fail due to pharmacokinetic and safety issues that could have been identified earlier. This Q&A explores how integrated ADME-Tox testing helps teams detect and address these risks during drug discovery.

Watch this on-demand webinar to explore how scientific depth and an integrated approach to drug development can help teams address increasingly complex development challenges more effectively.

Is your molecule ready for development? Explore a practical roadmap to help you identify risks, prioritise studies, and move toward IND or IMPD readiness with greater clarity.

A synthetic route that performs well at gram scale can fail abruptly during scale-up, where heat transfer, impurity pathways and operational variability expose hidden weaknesses. This article outlines three early red flags that signal a route may not withstand manufacturing conditions — and how identifying them early can prevent costly rework.

Lead optimization often stalls not because of a lack of data, but because the available data has not been translated into clear decisions. This article explores how disciplined, decision-led lead optimization strategies help discovery teams reduce uncertainty, focus experiments, and progress programs more predictably.

This article explores how disciplined, hypothesis-driven lead optimization can produce clearer SAR, reduce development risk, and help small-molecule programs progress more efficiently toward a clinical candidate.

A clean pharmacokinetics profile is often seen as a green light. But in practice, overly tidy PK data can hide analytical artefacts, non-linear behaviour, or poorly understood clearance mechanisms that surface later at significant cost.

Communication breakdowns rarely start as major problems, but small gaps in coordination can quietly slow progress and erode trust in CDMO partnerships.

Part 4: When “Too Busy” Becomes a Business Risk Even the most capable CDMO cannot deliver high-quality work if it is stretched too thin. As demand for outsourcing continues to rise across the life sciences sector, many CDMOs are operating near or beyond capacity. For pharma and biotech companies, this creates a silent but serious […]